Comment on FR Doc # 2026-10128

Summary: Fresenius Kabi USA, LLC opposes the proposed rule because it increases administrative complexity, reduces manufacturing flexibility, and risks exacerbating drug shortages. The company argues that the new subcategories and data requirements create significant compliance costs without improving the quota allocation process.